

1 **Original Research Article**

2 **Title Page**

3 **Title**

4 Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.

5

6 **Authors**

7 Malgorzata Mikulska <sup>1,2\*</sup>, Laura Ambra Nicolini <sup>2</sup>, Alessio Signori <sup>3</sup>, Antonio Di Biagio <sup>1,2</sup>,  
8 Chiara Sepulcri <sup>1</sup>, Chiara Russo <sup>1</sup>, Silvia Dettori <sup>1</sup>, arco Berruti <sup>1</sup>, Maria Pia Sormani <sup>3</sup>, Daniele  
9 Roberto Giacobbe <sup>1,2</sup>, Antonio Vena <sup>2</sup>, Andrea De Maria <sup>1,2</sup>, Chiara Dentone <sup>2</sup>, Lucia  
10 Taramasso <sup>2</sup>, Michele Mirabella <sup>1,2</sup>, Laura Magnasco <sup>1,2</sup>, Sara Mora <sup>4</sup>, Emanuele Delfino <sup>2</sup>,  
11 Federica Toscanini <sup>2</sup>, Elisa Balletto <sup>1,2</sup>, Anna Ida Alessandrini <sup>2</sup>, Federico Baldi <sup>1</sup>, Federica  
12 Briano <sup>1</sup>, Marco Camera <sup>2</sup>, Ferdinando Dodi <sup>2</sup>, Antonio Ferrazin <sup>2</sup>, Laura Labate <sup>1</sup>, Giovanni  
13 Mazzarello <sup>2</sup>, Rachele Pincino <sup>1</sup>, Federica Portunato <sup>2,5</sup>, Stefania Tutino <sup>1</sup>, Emanuela Barisione  
14 <sup>6</sup>, Bianca Bruzzone <sup>7</sup>, Andrea Orsi <sup>7,8</sup>, Eva Schenone <sup>2</sup>, Nirmala Rosseti <sup>2</sup>, Elisabetta Sasso <sup>9</sup>,  
15 Giorgio Da Rin <sup>10</sup>, Paolo Pelosi <sup>11,12</sup>, Sabrina Beltramini <sup>9</sup>, Mauro Giacomini <sup>4</sup>, Giancarlo  
16 Icardi <sup>7,8</sup>, Angelo Gratarola <sup>13</sup>, Matteo Bassetti <sup>1,2</sup>

17

18 **Affiliations**

19 1. Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of  
20 Genoa, Genoa, Italy

21 2. Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

22 3. Section of Biostatistics, Department of Health Sciences, University of Genova, Genova,  
23 Italy

24 4. Department of Informatics, Bioengineering, Robotics and System Engineering, University  
25 of Genoa, Genoa, Italy

26 5 Infectious Diseases Unit, University of Campania Luigi Vanvitelli, Napoli

- 27 6. Interventional Pulmonology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 28 7. Hygiene Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- 29 8. Department of Health Sciences, University of Genoa
- 30 9. Pharmacy Complex Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- 31 10. Medicine Laboratory, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- 32 11. Department of Surgical Sciences and Integrated Diagnostics, University of Genova,
- 33 Genova, Italy
- 34 12. Anesthesia and Intensive Care, San Martino Policlinico Hospital, IRCCS for Oncology
- 35 and Neurosciences, Genoa, Italy
- 36 13. Department of Emergency and Urgency, San Martino Policlinico Hospital, IRCCS for
- 37 Oncology and Neurosciences, Genoa, Italy

38

39 **\*Corresponding author**

40 [m.mikulska@unige.it](mailto:m.mikulska@unige.it) (MM)

41

42 **Abstract**

43 Introduction

44 Coronavirus disease 2019 (COVID-19) can lead to respiratory failure due to severe immune  
45 response. Treatment targeting this immune response might be beneficial but there is limited  
46 evidence on its efficacy.

47 The aim of this study was to determine if early treatment of patients with COVID-19  
48 pneumonia with tocilizumab and/or steroids was associated with better outcome.

49 Methods

50 This observational single-center study included patients with COVID-19 pneumonia who  
51 were not intubated and received either standard of care (SOC, controls) or SOC plus early  
52 (within 3 days from hospital admission) anti-inflammatory treatment. SOC consisted of  
53 hydroxychloroquine 400mg bid plus, in those admitted before March 24<sup>th</sup>, also  
54 darunavir/ritonavir. Anti-inflammatory treatment consisted of either tocilizumab (8mg/kg  
55 intravenously or 162mg subcutaneously) or methylprednisolone 1 mg/kg for 5 days or both.  
56 Failure was defined as intubation or death, and the endpoints were failure-free survival  
57 (primary endpoint) and overall survival (secondary) at day 30. Difference between the groups  
58 was estimated as Hazard Ratio by a propensity score weighted Cox regression analysis  
59 ( $HR_{OW}$ ).

60 Results

61 Overall, 196 adults were included in the analyses. They were mainly male (67.4%), with  
62 comorbidities (78.1%) and severe COVID-19 pneumonia (83.7%). Median age was 67.9  
63 years (range, 30-100) and median  $PaO_2/FiO_2$  200 mmHg (IQR 133-289). Among them,  
64 130 received early anti-inflammatory treatment with: tocilizumab (n=29, 22.3%),  
65 methylprednisolone (n=45, 34.6%), or both (n=56, 43.1%). The adjusted failure-free survival  
66 among tocilizumab/methylprednisolone/SOC treated patients vs. SOC was 80.8% (95%CI,  
67 72.8-86.7) vs. 64.1% (95%CI, 51.3-74.0),  $HR_{OW}$  0.48, 95%CI, 0.23-0.99; p=0.049. The

68 overall survival among tocilizumab/methylprednisolone/SOC patients vs. SOC was 85.9%  
69 (95%CI, 80.7-92.6) vs. 71.9% (95%CI, 46-73), HR<sub>OW</sub> 0.41, 95%CI: 0.19-0.89, p=0.025.

70 Conclusion

71 Early adjunctive treatment with tocilizumab, methylprednisolone or both may improve  
72 outcomes in non-intubated patients with COVID-19 pneumonia.

73

74

75 **Keywords:** Tocilizumab, interleukin-6, SARS-CoV-2, steroids, pneumonia, ARDS, COVID-  
76 19, treatment.

77

## 78 **Introduction**

79 Pandemic coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 coronavirus has  
80 recently emerged [1]. Although most of the infected patients will remain asymptomatic or  
81 develop mild symptoms, up to 20% may develop severe disease with pneumonia and  
82 respiratory failure [2]. Oxygen administration is the cornerstone of supportive treatment and  
83 is required in approximately 15% of cases, while invasive mechanical ventilation is necessary  
84 in up to 5-7% of severe cases [3-5]. Since mortality in patients with invasive ventilation can  
85 be very high, halting the progression from moderate to severe respiratory failure should  
86 reduce the mortality in COVID-19 [6].

87 At the beginning of COVID-19 pandemics, based on the experience with previous studies in  
88 viral pneumonia, including SARS-CoV and MERS, the use of steroids was discouraged,  
89 mainly due to undocumented benefit and fearing potential increase in viral proliferation and  
90 side effects [7, 8]. However, with the increasing knowledge about COVID-19, a biphasic  
91 model of the disease has been proposed [9, 10]. According to this model, the first phase is  
92 caused directly by viral replication, while in the second phase, the symptoms and respiratory  
93 failure are due to inflammatory response, and could be treated with agents which reduce  
94 inflammation, such as corticosteroids, or inhibitors of pro-inflammatory interleukins and  
95 Janus kinase (JAK) [9-11].

96 Indeed, some real life experiences in COVID-19 patients showed that the use of anti-  
97 inflammatory treatments might be beneficial [12]. In fact, short-term steroid therapy was  
98 associated with lower mortality in 201 patients with acute respiratory distress syndrome  
99 (ARDS) [13]. Additionally, following the data on presence of inflammatory cytokine storm in  
100 severe COVID-19, tocilizumab use has been advocated. This monoclonal antibody, which  
101 binds to interleukin 6 (IL-6) receptor and blocks the IL-6 mediated inflammatory response, is  
102 approved for treatment of rheumatologic disorders and cytokine-release syndrome associated

103 with Chimeric Antigen Receptor T-cell (CAR-T) administration. It was reported to reduce  
104 COVID-19-associated inflammation, and was approved in China for this indication [12, 14].  
105 Based on the first evidences, we formulated the hypothesis of potential benefit of anti-  
106 inflammatory treatment, and progressively modified our therapeutic approach to COVID-19.  
107 We started using tocilizumab in patients with respiratory failure, and subsequently, we  
108 introduced into our protocol early administration of methylprednisolone treatment, followed  
109 in more severe cases by the administration of tocilizumab.  
110 We hypothesized that outcomes such as no need for intubation and survival of patients with  
111 severe COVID-19 pneumonia in whom tocilizumab and/or methylprednisolone were  
112 administered in addition to standard of care (SOC) could be better than in those who received  
113 only SOC.

114

## 115 **Patients and methods**

### 116 Setting and patients

117 In this observational single-center study, adult patients admitted to the San Martino  
118 University Hospital, Genova, Italy, for COVID-19 pneumonia were included as cases if  
119 treated with tocilizumab and/or methylprednisolone, not intubated, not treated with remdesivir  
120 and not pregnant. The outcomes of patients treated with tocilizumab/methylprednisolone were  
121 compared to data from consecutive patients admitted to our hospital for COVID-19  
122 pneumonia who received only SOC, mainly because they were admitted before the routine  
123 use of tocilizumab/methylprednisolone (control group).

124 All patients provided an informed consent for treatment with off label agents according to the  
125 local protocol approved by Hospital Authorities, for data collection and for participation in  
126 the study. The study was carried out in accordance with the principles of the Declaration of  
127 Helsinki and approved by the Regional Ethic Committee (N. CER Liguria 114/2020-ID  
128 10420).

129 Data collection and definitions

130 Data were collected from hospital information system by a standard based automatic  
131 procedure and stored in an online database with pseudo-anonymization features suitable for  
132 secondary use of clinical data [15]. Controls were identified through this prospectively  
133 collected database of hospital-admitted COVID-19 patients.

134 Patients who had any of the following features at the time of, or after, admission were  
135 classified as having severe pneumonia: (1) respiratory distress ( $\geq 30$  breaths per min); or (2)  
136 oxygen saturation at rest  $\leq 93\%$ ; or (3) ratio of partial pressure of arterial oxygen to fractional  
137 concentration of oxygen inspired air ( $\text{PaO}_2/\text{FiO}_2$ )  $\leq 300$  mm Hg; or (4) severe disease  
138 complications (e.g., respiratory failure, requirement of mechanical ventilation, septic shock,  
139 or non-respiratory organ failure) [7, 14, 15].

140 Systemic inflammation was defined as presence at baseline of one of the following: fever  $>$   
141  $38^\circ\text{C}$ , C-reactive protein (CRP) 10 times above the upper limit of normal (ULN) of 5 mg/dl,  
142 ferritin 2 times above the ULN (400  $\mu\text{g/L}$ ), or IL-6 10 times above the ULN of 3.4 ng/L. The  
143 first results obtained at hospital admission, and in any case not later than within day 3 of  
144 admission were considered.

145 Adverse events possibly or probably related to steroid and tocilizumab treatment, such as  
146 neutropenia, anemia, thrombocytopenia, increase in alanine aminotransferase (ALT) levels,  
147 (UNL  $< 40$  U/L), microbiologically documented infections and allergic reactions were  
148 evaluated for both treated patients and controls. Adverse events were collected up to the last  
149 available follow up from starting of tocilizumab and/or methylprednisolone in treatment  
150 group and from hospital admission in the control group. The common terminology criteria for  
151 adverse event (CTCAE) version 5.0 was used.

152 Standard of care and treatment procedures

153 The diagnosis of COVID-19 was made with a positive RT-PCR assay performed on nasal  
154 swab or bronchoalveolar lavage fluid according to World Health Organization interim guidance

155 [16]. Patients received treatment with oral hydroxychloroquine 400mg bid, unless glucose-6-  
156 phosphate dehydrogenase deficient. Until March 24<sup>th</sup>, darunavir/ritonavir 800/100 qd was also  
157 administered [17]. Thereafter, the protocol was amended and darunavir/ritonavir was  
158 withdrawn [18]. Short-term antibiotic coverage was prescribed at admission. Low-molecular-  
159 weight heparin prophylaxis was administered unless contraindicated. These treatments were  
160 defined as SOC.

161 Since March 11<sup>th</sup>, we started adding tocilizumab to SOC in case of severe COVID-19  
162 pneumonia and systemic inflammation. Tocilizumab was administered intravenously at the  
163 dose of 8mg/kg (maximum 800mg), with the possibility of repeating the dose after 24 hours if  
164 no response was obtained. Due to a temporary shortage of intravenous formulation, the  
165 available subcutaneous formulation (162 mg) was administered. Following an internal review  
166 of risks and benefits of steroid treatment in patients with severe COVID-19, since March 16<sup>th</sup>  
167 methylprednisolone (1mg/kg for 5 days intravenously, then 0.5mg/kg for 5 days) was  
168 included in the protocol. Tocilizumab was added in case of systemic inflammation or rapid  
169 respiratory function deterioration.

#### 170 Statistical analysis

171 No sample-size calculations were performed. The primary end point was time to failure,  
172 defined as intubation and mechanical ventilation or death, whichever occurred first, within 30  
173 days from the hospital admission.

174 The secondary endpoint was overall survival (OS). Time was calculated from time of  
175 hospitalization for the comparison between tocilizumab/methylprednisolone/SOC and SOC  
176 patients and from the date of starting anti-inflammation treatment for the comparison among  
177 treatment groups.

178 The landmark analysis was applied in order to minimize the potential immortal time bias that  
179 can arise in non-randomized studies and is related to the fact that patients treated after a  
180 longer time from admission must have not experienced the event up to that time, and that



181 patients with a very early event (e.g. death) were more likely assigned to the untreated group.  
182 This is a conservative analysis which reduced the risk that the treatment choice was motivated  
183 by the patient's disease course. Therefore, day 3 from hospital admission was set as a  
184 landmark time point: those who died, were intubated or discharged from the hospital before  
185 day 3 were excluded, while patients were included in the tocilizumab/methylprednisolone  
186 treatment group if the treatment was started within 3 days from hospital admission (see Figure  
187 1).

188 To minimize baseline differences between treated and untreated patients a propensity score-  
189 based analysis was performed. Propensity score (PS) was derived by a logistic regression  
190 model including the following baseline variables: age, gender, presence of comorbidities and  
191 week of treatment start, ratio of partial pressure of arterial oxygen to fractional concentration  
192 of oxygen inspired air ( $\text{PaO}_2/\text{FiO}_2$ ), non-invasive ventilation (NIV), time from symptoms  
193 onset to hospital admission, IL-6, ferritin, C-reactive protein (CRP) and d-dimer serum levels.  
194 Positivity assumption of PS was checked after the calculation. For each patient, the overlap  
195 weight (OW) based on PS was calculated [19]. To assess the balance of covariate distribution  
196 between the two groups, Cohen's standardized mean differences were calculated between the  
197 two groups in the original samples and after weighting. An absolute value of difference  $< 0.10$   
198 was considered an acceptable balance.

199 The OW-weighted Cox proportional hazard regression model was used to calculate the  
200 adjusted hazard-ratio ( $\text{HR}_{\text{OW}}$ ) of tocilizumab/methylprednisolone/SOC vs SOC patients.  
201 Weighted cumulative probability of failure or death was calculated by mean of Kaplan-Meier  
202 (KM) survival curves.

203 To define risk factors associated with outcomes and to compare the three treatment groups,  
204 adjusted HRs were estimated by a multivariable Cox proportional hazard regression model.  
205 The same baseline variables used in the calculation of PS were considered for the  
206 multivariable analysis. To avoid overfitting, only those characteristics who showed a p-value

207  $\leq 0.15$  at univariable analysis and after inclusion in the multivariable model were considered,  
208 with age and gender forced into the model. For a better interpretation and to avoid the  
209 influence of outliers on estimation, the IL-6, ferritin, CRP and d-dimer were log-transformed  
210 before the analysis due to the highly skewed distribution. All results were reported as HR with  
211 95% confidence interval (95%CI).

212 A subgroup analysis was performed to assess if the treatment effect of tocilizumab versus  
213 methylprednisolone on primary outcome was different between subgroups defined according  
214 to categorized baseline variables. An interaction test was used to assess a different treatment  
215 effect in subgroups.

216 The sensitivity analysis was pre-planned, and the comparison between  
217 tocilizumab/methylprednisolone/SOC and SOC patients was reassessed excluding from the  
218 SOC group the patients that received tocilizumab or methylprednisolone after 3 days from  
219 hospitalization. The PS and OW were recalculated.

220 P was considered significant if  $\leq 0.05$ . Stata (v.16; StataCorp.) was used for the computation.

221

## 222 **Results**

### 223 Patients

224 Overall, 215 patients were evaluated: 135 (62.8%) received tocilizumab/methylprednisolone  
225 within 3 days from hospitalization, 20 (12.9%) were treated after 3 days from hospitalization  
226 and were included in the SOC group, and 60 (38.7%) patients received only SOC. After  
227 excluding the patients who were discharged or developed a failure event (intubation or death)  
228 before the day 3 set for landmark analysis, 196 patients were included (130  
229 tocilizumab/methylprednisolone/SOC and 66 SOC patients) (Figure 1).

230 Patients were mainly male (67.4%), with a median age of 67.9 years (range, 30-100), and  
231 most of them (78.1%) had comorbidities (Table 1). The median  $\text{PaO}_2/\text{FiO}_2$  was 200 mmHg  
232 (interquartile range, IQR 133-289), and 164 (83.7%) had severe pneumonia ( $\text{PaO}_2/\text{FiO}_2$

233 <300mmHg). The median time from the onset of symptoms to anti-inflammatory treatment in  
234 130 patients was 8 days, IQR: 9-15; range 5-23.

### 235 Failure rate

236 In univariable and multivariable analyses, older age, male gender, higher baseline  
237 inflammatory markers, especially IL-6, and  $\text{PaO}_2/\text{FiO}_2 < 100$  mmHg were identified as risk  
238 factors for failure (Table 2).

239 Differences between the two groups were consistently reduced after OW. OW weighted  
240 characteristics of two groups of patients are shown in Table 3.

241 After a median follow-up of 49 days (range 4-70, IQR 30-56), 17 patients were intubated  
242 (14/130 in tocilizumab/methylprednisolone/SOC and 3/66 in SOC group) and 36 died (14/130  
243 in tocilizumab/methylprednisolone/SOC and 22/66 in SOC group). Overall, 28 (21.5%)  
244 failure events were detected among tocilizumab/methylprednisolone/SOC patients and 25  
245 (37.9%) among SOC patients.

246 At day 14, the weighted failure-free survival was 86.5% (95%CI, 79.1-91.7) among  
247 tocilizumab/methylprednisolone/SOC and 75.8% (95%CI, 63.7-84.1) among SOC patients,  
248 while at 30 days (primary endpoint) it was, respectively, 80.8% (95%CI, 72.8-86.7) and  
249 64.1% (95%CI, 51.3-74.0) (Figure 2). The Cox regression analysis adjusted by OW weighted  
250 propensity score estimated a significant effect of therapy in reducing the risk of failure ( $\text{HR}_{\text{OW}}$   
251 = 0.48 95%CI, 0.23-0.99;  $p=0.049$ ).

### 252 Tocilizumab/methylprednisolone treatment strategies

253 Within the cohort of 130 treated patients, 45 (34.6%) received methylprednisolone, 29  
254 (22.3%) tocilizumab and 56 (43.1%) combined therapy. Patients in combined treatment group  
255 were younger and with fewer comorbidities but with comparable inflammatory markers, the  
256 frequency of low  $\text{PaO}_2/\text{FiO}_2$  and NIV (Table 4).

257 After a median follow-up of 53 days (range 4-70, interquartile range 33-57), 28 failures were  
258 observed: in 14/45 (31.1%) patients receiving methylprednisolone, 6/29 (20.7%) tocilizumab  
259 (1 subcutaneously and 5 intravenously) and 8/56 (14.3%) in combined treatment group.

260 At 14 days of follow-up from treatment start, the failure-free survival (Figure 3) was 80%  
261 (95%CI, 65.1-89.1) in methylprednisolone group, 79.3% (95%CI, 59.6-90.1) in tocilizumab  
262 group and 87.5% (95 CI, 75.6-93.8) in combined therapy group. No significant differences  
263 between the three treatment groups were identified in a multivariable analysis adjusted for the  
264 baseline risk factors (p for heterogeneity among treatment groups= 0.45) (Table 5).

#### 265 Overall survival (OS)

266 A total of 45 deaths, 36 without a previous intubation, were registered during the follow-up:  
267 23 (34.8%) were in the SOC and 22 (16.9%) in tocilizumab/methylprednisolone/SOC group.

268 At day 14 of follow-up, the OS was 92.7% (95%CI, 86.4-96.1) in  
269 tocilizumab/methylprednisolone/SOC group and 78.2% (95%CI, 67.0-85.6) in SOC (Figure  
270 4). At 30 days OS was, respectively, 85.9% (95%CI, 80.7-92.6) and 71.9% (95%CI, 59.9-  
271 80.8), with a significant better survival in tocilizumab/methylprednisolone/SOC patients in  
272 OW analysis ( $HR_{OW} = 0.41$ , 95%CI: 0.19-0.89,  $p=0.025$ ).

273 When considering only patients receiving tocilizumab/methylprednisolone/SOC, death  
274 occurred in 13/45 (28.9%) patients receiving methylprednisolone, 4/29 (13.8%) tocilizumab  
275 and 5/56 (8.9%) in those receiving combined therapy. At 30 days the OS was, 79.5% (95%CI,  
276 64.2-88.8), 85.8% (95%CI, 66.5-94.4) and 90.9% (95%CI, 79.6-96.1) in patients treated,  
277 respectively, with methylprednisolone, tocilizumab and combined therapy (adjusted p for  
278 heterogeneity among treatments: 0.55).

#### 279 Subgroup analyses

280 It was not possible to identify subgroups, based on demographic or clinical characteristics,  
281 with different benefits of tocilizumab versus methylprednisolone or tocilizumab versus  
282 combination therapy.

### 283 Sensitivity analyses

284 As a sensitivity analysis, we run the comparison between  
285 tocilizumab/methylprednisolone/SOC and SOC patients excluding the 20 patients that  
286 received tocilizumab/methylprednisolone treatment after 3 days from hospital admission (6  
287 methylprednisolone, 8 tocilizumab and 6 both), and experienced 5 (25%) failures. The  
288 weighted failure-free survival in the SOC group was now 72.5% (95%CI, 58.8-81.5) at 14  
289 days and 67.1% (95%CI, 52.8-77.9) after 30 days. The OW weighted difference between  
290 tocilizumab/methylprednisolone/SOC and SOC patients was amplified ( $HR_{OW}=0.39$ ; 95%CI,  
291 0.17-0.89;  $p=0.026$ ).

### 292 Side effects

293 Among 155 patients who received tocilizumab/methylprednisolone/SOC at any time, 106  
294 (68%) developed ALT increase (grade 1-2: 98/155, 63% and grade 3: 8/155, 5%): 32.4% of  
295 those who received methylprednisolone/SOC and 77% of those who received  
296 tocilizumab/SOC +/- methylprednisolone. Microbiologically documented infections were  
297 recorded in 12 (7.7%) patients: 10 bloodstream infections, 2 ventilator-associated pneumonias  
298 and 2 urinary tract infections. In tocilizumab/methylprednisolone/SOC group, grade 4  
299 transient neutropenia and grade 2 maculopapular rash occurred in 1 patient each.

300 Among 60 SOC patients, grade 1-2 ALT increase occurred in 5 (8%) and 1 patient developed  
301 urinary tract infection.

302 There were no cases of significant decrease of hemoglobin or platelet levels.

303

### 304 **Discussion**

305 In this observational study in not intubated patients with mainly severe COVID-19  
306 pneumonia, the early addition of tocilizumab and/or methylprednisolone to SOC resulted in  
307 adjusted failure-free survival of 86.5% and 80.8% at day 14 and 30, which was, respectively,  
308 10.7% and 16.7% higher than in SOC patients.

309 Even though only the minority of patients develop the severe form of COVID-19 (14% in the  
310 Chinese cohort of 72,314 patients), the outcomes in this group are poor, with 24.9% rate of  
311 failure (intubation or death) reported in 173 patients with severe disease [2, 20]. The  
312 observation that COVID-19-associated respiratory failure can be caused by cytokine storm  
313 rather than viral progression is the rationale for administering anti-inflammatory treatments,  
314 including tocilizumab [9, 10, 21]. The initial studies on tocilizumab in COVID-19 reported a  
315 clinical benefit in retrospective cohorts of 21 and 15 patients with moderate to critical  
316 COVID-19 pneumonia, in whom steroids were also administered [12, 22]. However, none of  
317 studies reported and evaluated the impact of steroid co-administration, nor included a control  
318 group which did not receive tocilizumab. Subsequently these treatments were recommended  
319 by Chinese Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (version 6  
320 and 7) [14]. However, considering the rapid widespread increase in severe cases of COVID-  
321 19 worldwide, the availability and the cost of anti-IL-6 treatment might limit its use.  
322 Therefore, at the peak of COVID-19 epidemics in our city, we implemented the early use of  
323 corticosteroids and the use of subcutaneous tocilizumab if intravenous formulation was not  
324 readily available. We acknowledge that the benefit of subcutaneous formulation might be  
325 lower and slower than in case of intravenous drug, but no standard intravenous dose for  
326 COVID-19 has been established, as one study used 400 mg and the other the range of doses  
327 from 80 mg to 600 mg, irrespective of the patients' weight [12, 22].  
328 The first study that reported the impact of steroid treatment in COVID-19, showed that it was  
329 administered to 30.8% of patients, mainly in case of more severe disease, and was associated  
330 with a significant reduction of the risk of death in patients with ARDS (HR=0.38) [13]. While  
331 other cohorts reported steroid use in approximately 44% of severely ill patients, they did not  
332 analyze their influence on outcome [20, 23]. Subsequently, an observational study reported a  
333 benefit of early administration of steroid therapy on composite outcome of ICU admission,  
334 mechanical ventilation or death at 14 days (34.9% vs. 54.3%) and overall survival (86.4% vs.

335 73.7%) [24]. In addition to these data, we were able to demonstrate that, after minimizing as  
336 much as possible the differences between the groups through OW adjustment, the outcome of  
337 patients was better in case of early treatment with tocilizumab and/or methylprednisolone.  
338 Indeed, in SOC group the rate of failure at day 14 of 24.2% was very similar to what reported  
339 in other cohorts with severe pneumonia (24.9%), while it was reduced to 13.5% in our  
340 tocilizumab/methylprednisolone/SOC group [20]. Our data show that this benefit was also  
341 present with month-long follow up (overall  $HR_{ow}$  of 0.48), which is important in establishing  
342 long term prognosis of these patients. Moreover, the benefit of early  
343 tocilizumab/methylprednisolone was also noted on overall survival, both at 14 and 30 days  
344 (respectively, 92.7% vs. 78.2% and 85.9% vs. 71.9%). Compared to the study with steroid use  
345 only, the 14-day survival was higher in our cohort, providing background for the hypothesis  
346 that combined tocilizumab/steroid treatment might be warranted [24]. Finally, preliminary  
347 results of the RECOVERY trial reported higher survival rate in patients with severe COVID-  
348 19 pneumonia treated with dexamethasone, although the detailed results are not available yet.  
349 Interestingly, our observational study, which showed the effectiveness of early anti-inflammatory  
350 treatment in a cohort of non-intubated patients with severe COVID-19 pneumonia,  
351 documented that these patients were treated at a median time of 8 days after the onset of  
352 symptoms, which is exactly the time of initial cytokine storm, and therefore might be optimal  
353 for the effect of anti-inflammatory treatment.

354 Consistent with other studies, we identified older age, high IL-6 levels and poor respiratory  
355 function as independent predictors of failure, with possible impact also of CRP and d-dimer  
356 levels [25]. Possibly due to a limited sample size, we were unable to document which of three  
357 treatment groups provided most benefit, and if there were predictors of better response to  
358 tocilizumab/methylprednisolone compared to methylprednisolone alone in any subset of  
359 patients. However, the rate of failure-free survival was the highest in the combination  
360 treatment group. In addition, based on our sensitivity analyses, adding the anti-inflammatory

361 treatment later after hospital admission might still provide some clinical benefit. In fact,  
362 including in the SOC group patients who received anti-inflammatory treatment later during  
363 the infectious course possibly reduced the difference between the study arms, highlighting the  
364 benefit of an early anti-inflammatory treatment.

365 The limitations of this study include the non-randomized design, yet the inclusion of  
366 consecutive patients using the same SOC but not treated with tocilizumab or  
367 methylprednisolone, and adjustment for the outcome-associated variables, allowed to notice  
368 the improvement in patient outcomes. Nonetheless, it is possible that some benefit observed  
369 was partially due to general improvements in patient clinical care that occur with time.  
370 Additionally, this being a single-center experience might limit the applicability to other  
371 settings, since our hospital managed to rapidly increase the capacity for hospitalization and  
372 ventilation support, potentially improving general patient care. However, the adjustment for  
373 the differences between patient groups through propensity score and conservative approach  
374 with the use of landmark analysis were directly at minimizing the risk associated with an  
375 absence of randomization. Finally, we believe that the rate of failure observed in this study of  
376 7.3% at 14 days in those with severe COVID-19 treated with SOC and  
377 tocilizumab/methylprednisolone might help to better define the expected rate of response and  
378 calculate the number of patients needed to include in the studies assessing various treatment  
379 options.

## 380 **Conclusion**

381 In conclusion, the negative impact of immune response in COVID-19 might be mitigated by  
382 early administration of anti-inflammatory therapy with tocilizumab, methylprednisolone or  
383 both. Randomized studies are warranted to establish the best treatment options, their timing  
384 and limitations.

385



386 **Acknowledgments**

387 We would like to thank all the patients and the hospital staff, with particular mention of Mrs

388 Enrica Lombardi, who helped us to get through these difficult weeks.

389 This study was supported by the efforts of all members of GECOVID group.

390

391 **Funding**

392 No funding or sponsorship was received for this study or publication of this article.

393 Independently of the study, Roche provided intravenous tocilizumab free of charge for the

394 Ligurian Region during the first weeks of COVID-19 epidemics.

395 Some of the patients were included also in the observational Italian national AIFA study on

396 intravenous tocilizumab.

## 397 **References**

- 398 [1] Zhou F, Yu T, Du R, et al. (2020) Clinical course and risk factors for mortality of  
399 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*  
400 395(10229): 1054-1062. [10.1016/s0140-6736\(20\)30566-3](https://doi.org/10.1016/s0140-6736(20)30566-3)
- 401 [2] Wu Z, McGoogan JM (2020) Characteristics of and Important Lessons From the  
402 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314  
403 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*.  
404 [10.1001/jama.2020.2648](https://doi.org/10.1001/jama.2020.2648)
- 405 [3] Grasselli G, Zangrillo A, Zanella A, et al. (2020) Baseline Characteristics and  
406 Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy  
407 Region, Italy. *JAMA*. [10.1001/jama.2020.5394](https://doi.org/10.1001/jama.2020.5394)
- 408 [4] Severe acute respiratory infections treatment centre: practical manual to set up and  
409 manage a SARI treatment centre and SARI screening facility in health care facilities. Geneva:  
410 World Health Organization; 2020 (WHO/2019-nCoV/SARI\_treatment\_center/2020.1).
- 411 [5] Yang X, Yu Y, Xu J, et al. (2020) Clinical course and outcomes of critically ill  
412 patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,  
413 observational study. *Lancet Respir Med*. [10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5)
- 414 [6] Richardson S, Hirsch JS, Narasimhan M, et al. (2020) Presenting Characteristics,  
415 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the  
416 New York City Area. *JAMA*. [10.1001/jama.2020.6775](https://doi.org/10.1001/jama.2020.6775)
- 417 [7] Clinical management of severe acute respiratory infection (SARI) when COVID-19  
418 disease is suspected. Interim guidance 13 March 2020. WHO/2019-nCoV/clinical/2020.4.
- 419 [8] Russell CD, Millar JE, Baillie JK (2020) Clinical evidence does not support  
420 corticosteroid treatment for 2019-nCoV lung injury. *The Lancet* 395(10223): 473-475.  
421 [10.1016/S0140-6736\(20\)30317-2](https://doi.org/10.1016/S0140-6736(20)30317-2)

- 422 [9] Zhang W, Zhao Y, Zhang F, et al. (2020) The use of anti-inflammatory drugs in the  
423 treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of  
424 clinical immunologists from China. *Clin Immunol* 214: 108393-108393.  
425 [10.1016/j.clim.2020.108393](https://doi.org/10.1016/j.clim.2020.108393)
- 426 [10] Siddiqi HK, Mehra MR COVID-19 Illness in Native and Immunosuppressed States: A  
427 Clinical-Therapeutic Staging Proposal. *The Journal of Heart and Lung Transplantation*.  
428 [10.1016/j.healun.2020.03.012](https://doi.org/10.1016/j.healun.2020.03.012)
- 429 [11] Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic  
430 Treatments for Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*.  
431 [10.1001/jama.2020.6019](https://doi.org/10.1001/jama.2020.6019)
- 432 [12] Xu X, Han M, Li T, et al. (2020) Effective treatment of severe COVID-19 patients  
433 with tocilizumab. *ChinaXiv*
- 434 [13] Wu C, Chen X, Cai Y, et al. (2020) Risk Factors Associated With Acute Respiratory  
435 Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in  
436 Wuhan, China. *JAMA internal medicine*. [10.1001/jamainternmed.2020.0994](https://doi.org/10.1001/jamainternmed.2020.0994)
- 437 [14] Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th  
438 edition). March 4, 2020. Issued by: China National Health Commission.
- 439 [15] (2018) From Liguria HIV Web to Liguria Infectious Diseases Network: How a Digital  
440 Platform Improved Doctors' Work and Patients' Care. *AIDS Research and Human*  
441 *Retroviruses* 34(3): 239-240. [10.1089/aid.2017.0064](https://doi.org/10.1089/aid.2017.0064)
- 442 [16] WHO (2020) Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected  
443 human cases. 2020. [https://www.who.int/publications-detail/laboratory-testing-for-2019-  
444 novel-coronavirus-in-suspected-human-cases-](https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-).
- 445 [17] Bassetti M, Giacobbe DR, Aliberti S, Barisione E, Centanni S, De Rosa FG, Di Marco  
446 F, Gori A, Granata G, Mikulska M, et al: Balancing evidence and frontline experience in the  
447 early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-

448 Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). *Clin Microbiol Infect*  
449 2020. Accepted for publication.

450 [18] Cao B, Wang Y, Wen D, et al. (2020) A Trial of Lopinavir-Ritonavir in Adults  
451 Hospitalized with Severe Covid-19. *N Engl J Med*. 10.1056/NEJMoa2001282

452 [19] Thomas LE, Li F, Pencina MJ (2020) Overlap Weighting: A Propensity Score Method  
453 That Mimics Attributes of a Randomized Clinical Trial. *JAMA*. 10.1001/jama.2020.7819

454 [20] Guan WJ, Ni ZY, Hu Y, et al. (2020) Clinical Characteristics of Coronavirus Disease  
455 2019 in China. *N Engl J Med*. 10.1056/NEJMoa2002032

456 [21] Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q (2020) The cytokine release syndrome  
457 (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may  
458 be the key to reduce the mortality. *International journal of antimicrobial agents*: 105954-  
459 105954. 10.1016/j.ijantimicag.2020.105954

460 [22] Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J (2020) Tocilizumab treatment in COVID-19:  
461 A single center experience. *J Med Virol*. 10.1002/jmv.25801

462 [23] Wang D, Hu B, Hu C, et al. (2020) Clinical Characteristics of 138 Hospitalized  
463 Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*.  
464 10.1001/jama.2020.1585

465 [24] Fadel R, Morrison AR, Vahia A, et al. (2020) Early Short Course Corticosteroids in  
466 Hospitalized Patients with COVID-19. *Clin Infect Dis*. 10.1093/cid/ciaa601

467 [25] Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Clinical predictors of mortality due  
468 to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care*  
469 *Med*. 10.1007/s00134-020-05991-x

470

471

472

473

474 **Tables**

475 **Table 1**

476 Unweighted patients' characteristics stratified for treatment group.

Characteristics	All (n=196)	Tocilizumab/ methylprednisolone/SOC (n=130)	SOC (n=66)	Standardized difference
Age, mean (SD); median (range)	67.5 (13.7); 67.9 (32-100)	64.5 (12.4); 65 (32-91)	73.5 (14.4); 76.2 (39-100)	0.67
Sex (male/female), n (%)	132/64 (67.4/32.7)	91/39 (70/30)	41/25 (62.1/37.9)	0.17
Any comorbidity, n (%)	153 (78.1)	198 (75.4)	55 (83.3)	0.19
Hypertension	77 (39.3)	48 (36.9)	29 (43.9)	
Diabetes	30 (15.3)	22 (16.9)	8 (12.1)	
Cancer	22 (11.2)	15 (11.5)	7 (10.6)	
Obesity	10 (5.1)	8 (6.2)	2 (3.0)	
Ischemic heart failure	22 (11.2)	11 (8.5)	11 (16.7)	
Hospital admission period				
≤ 11 <sup>th</sup> week of 2020	78 (39.8)	29 (22.3)	49 (74.2)	1.21
12 <sup>th</sup> week of 2020	66 (33.7)	51 (39.2)	15 (22.7)	0.36
13 <sup>th</sup> - 14 <sup>th</sup> week of 2020	52 (26.5)	50 (38.5)	2 (3.1)	0.97
Days from symptoms to hospital admission, mean (SD); median (range)	6.8 (4.1); 7 (0-24)	7.5 (4.1); 7 (0-24)	5.6 (4.0); 5 (0-19)	0.47
IL-6, mean (SD), median (IQR), ng/L	60.3 (120.3), 36.9 (22-64)	69.7 (144.8), 40 (27-73)	41.9 (36.1), 31.5 (16-56)	0.26
Ferritin, mean (SD), median (IQR), µg/L	1076 (1060), 762 (452-1424)	1251.4 (1194.4), 835 (526-1656)	730.2 (596.7), 588 (316-900)	0.55
CRP, mean (SD), median (IQR), mg/L	100.8 (85.3), 81 (40-132)	112 (91.3), 90 (45-147)	78.8 (67.2), 65 (30-102)	0.41
D-dimer, mean (SD), median	2340 (4091), 1125	2319 (4441), 1100 (670-	2382 (3327), 1173	0.02

(IQR), $\mu\text{g/L}$	(665-1730)	1569)	(651-2806)	
$\text{PaO}_2/\text{FiO}_2$ , mean (SD), median (IQR), mmHg	221 (108), 200 (133- 289)	214.8 (97.8) 199 (134- 277)	232.9 (124.3), 208 (130-308)	0.30
$\text{PaO}_2/\text{FiO}_2 < 100$ mmHg	22 (11.2)	13 (10)	9 (13.6)	0.11
$\text{PaO}_2/\text{FiO}_2 < 200$ mmHg	93 (47.5)	65 (50)	28 (42.4)	0.15
NIV, n (%)	73 (37.2)	64 (49.2)	9 (13.6)	0.63
Anti-inflammatory treatment				
Steroids only	-	45 (34.6)	-	-
Tocilizumab only	-	29 (22.3)	-	
Combination treatment	-	56 (43.1)		
Number of doses tocilizumab				
0		45 (34.6)	-	-
1	-	74 (56.9)	-	-
2	-	11 (8.5)	-	-
Route of administration of tocilizumab				
Intravenous	-	49 (57.6)	-	-
Subcutaneous	-	36 (42.4)	-	-

477 CRP, C reactive protein; IL-6, interleukin 6; NIV, non invasive ventilation;  $\text{PaO}_2/\text{FiO}_2$ , ratio  
 478 of partial pressure of arterial oxygen to fractional concentration of oxygen inspired air; SOC,  
 479 standard of care.

480 **Table 2**

481 Univariable and multivariable analyses of risk factors for failure.

Factors	Univariable		Multivariable	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (1-year change)	1.05 (1.03-1.07)	<0.001	1.05 (1.01-1.07)	<0.001
Sex (male vs. female)	1.91 (1.05-3.45)	0.033	1.77 (0.96-3.25)	0.066
Any comorbidity (Yes vs. No)*	3.85 (1.55-9.60)	0.004		
Treatment period		0.17		
≤ 11 <sup>th</sup> week of 2020	1.00 (ref)			
12 <sup>th</sup> week of 2020	0.90 (0.52-1.56)			
13 <sup>th</sup> - 14 <sup>th</sup> week of 2020	0.54 (0.27-1.07)			
Time from symptoms (>7 vs ≤ 7 days)	1.01 (0.61-1.67)	0.97		
IL-6 (1-unit on log-scale)	1.84 (1.45-2.33)	<0.001	1.70 (1.30-2.23)	<0.001
Ferritin (1-unit on log-scale)	1.10 (0.84-1.44)	0.47		
CRP (1-unit on log-scale)	1.61 (1.21-2.16)	0.001		
D-dimer (1-unit on log scale)	1.50 (1.20 - 1.87)	<0.001		
PaO <sub>2</sub> /FiO <sub>2</sub> <100 vs ≥100	3.12 (1.79-5.45)	<0.001	1.95 (1.10-3.46)	0.023
NIV	1.28 (0.78-2.09)	0.33		

482 CRP, C reactive protein; HR: hazard-ratio; IL-6, interleukin 6; NIV, non invasive ventilation;

483 PaO<sub>2</sub>/FiO<sub>2</sub>, ratio of partial pressure of arterial oxygen to fractional concentration of oxygen

484 inspired air.

485 \*None of the following single comorbidities resulted significant in multivariable analysis:  
486 hypertension, diabetes, cancer, obesity, ischemic heart failure, and only ischemic heart disease  
487 was significant in univariate analysis.  
488



489 **Table 3**

490 OW weighted patients' characteristics stratified for treatment group

Characteristics	Tocilizumab/methylprednisolone/SOC (n=130)	SOC (n=66)	Standardized weighted difference
Age, mean (SD); median (IQR)	68.4 (11.7); 68.3 (57.4-77.3)	68.4 (13); 68 (59.2-76.9)	0.000
Sex (male/female), n (%)	87/43 (67/33)	44/22 (67/33)	0.000
Any comorbidity, n (%)	102 (78.8)	52 (78.8)	0.000
Treatment period			
≤ 11 <sup>th</sup> week of 2020	68 (52.1)	35 (52.1)	0.000
12 <sup>th</sup> week of 2020	52 (40.0)	26 (40)	0.000
13 <sup>th</sup> - 14 <sup>th</sup> week of 2020	10 (7.9)	5 (7.9)	0.000
Days from symptoms to hospital admission, mean (SD); median (IQR)	7 (3.6); 7 (4-9)	6.8 (4.2); 7 (3-9)	0.071
Il-6, mean (SD); median (IQR), ng/L	45.2 (55.7); 37 (26-51)	45.2 (36.8); 32.4 (17-64)	0.000
Ferritin, median (IQR), µg/L	901 (671); 762 (491-1095)	901 (727); 706 (479-995)	0.000
PCR, median (IQR), mg/L	90.6 (65.3); 73 (43-124)	90.6 (83.3); 63.1 (30-131)	0.000

D-dimer, median (IQR)	1764 (3110); 1080 (680-1500)	1764 (2372); 1030 (651-1691)	0.000
PaO <sub>2</sub> /FiO <sub>2</sub> , mean (SD); median (IQR), μg/L	211.6 (96.1); 196 (144-280)	211.6 (118); 180 (123-291)	0.000
NIV, n (%)	53 (41.1)	27 (41.1)	0.000

NIV, non invasive ventilation; OW: overlap weights; PaO<sub>2</sub>/FiO<sub>2</sub>, ratio of partial pressure of arterial oxygen to fractional concentration of oxygen inspired air; SOC, standard of care.

491

492 Table 4

493 Clinical and demographic characteristics in treated patients included in outcome analyses

Characteristics	Methylprednisolone (n=45)	Tocilizumab (n=29)	Combined (n=56)
Age, mean (SD); median (range)	67.5 (13.9); 68.2 (37-91)	65.9 (10.2); 67.4 (42-80)	61 (11.7); 63 (32-85)
Sex (male/female), n (%)	32/13 (71.1/28.9)	24/5 (82.8/17.2)	35/21 (62.5/37.5)
Any comorbidity, n (%)	36 (80)	23 (79.3)	39 (69.6)
Treatment period			
≤ 11 <sup>th</sup> week of 2020	4 (8.9)	22 (75.8)	3 (5.4)
12 <sup>th</sup> week of 2020	30 (66.7)	6 (20.7)	15 (26.8)
13 <sup>th</sup> - 14 <sup>th</sup> week of 2020	11 (24.4)	1 (3.5)	38 (67.9)
Days from symptoms to hospital admission, mean (SD); median (range)	7.2 (4.7); 7 (0-21)	7.7 (3.5); 8 (1-15)	7.6 (3.8); 7 (2-24)
IL-6, median (IQR), ng/L	40 (22-68)	45 (33-88)	37 (27-63)
Ferritin, median (IQR), µg/L	741 (380-1087)	1422 (845-1846)	760 (444-1858)
CRP, median (IQR), mg/L	82 (43-124)	121 (52-218)	88 (44-153)
D-dimer, median (IQR), µg/L	1080 (730-1600)	1280 (950-2500)	1055 (618-1411)
PaO <sub>2</sub> /FiO <sub>2</sub> , median (IQR), mmHg	201 (156-311)	203 (144-280)	190 (125-254)
PaO <sub>2</sub> /FiO <sub>2</sub> < 100 mmHg	6 (13.3)	1 (3.5)	6 (10.7)
PaO <sub>2</sub> /FiO <sub>2</sub> < 200 mmHg	22 (48.9)	13 (44.8)	30 (53.6)

NIV, n (%)	20 (44.4)	13 (44.8)	31 (55.4)
Number of doses tocilizumab			
0		-	-
1		22 (75.9)	54 (96.4)
2		7 (24.1)	2 (3.6)
Route of administration of tocilizumab			
Intravenous		18 (62.1)	31 (55.4)
Subcutaneous		11 (37.9)	25 (44.6)

494 CRP, C reactive protein; IL-6, interleukin 6; NIV, non invasive ventilation; PaO<sub>2</sub>/FiO<sub>2</sub>, ratio

495 of partial pressure of arterial oxygen to fractional concentration of oxygen inspired air.

496

497 Table 5

498 Univariable and multivariable analyses for risk factors of failure endpoint in patients treated with  
 499 tocilizumab and/or methylprednisolone and standard of care (SOC).

500

Factors	Univariable		Multivariable	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Treatment		0.17		0.45
Methylprednisolone	1.00 (ref)		1.00 (ref)	
Tocilizumab	0.69 (0.27-1.81)		0.65 (0.23-1.82)	
Combined	0.45 (0.19-1.06)		0.59 (0.24-1.43)	
Age (1-year change)	1.05 (1.02-1.09)	0.002	1.05 (1.01-1.09)	0.012
Sex (male vs. female)	1.68 (0.68-4.14)	0.26	1.54 (0.61-3.91)	0.37
Any comorbidity (Yes vs. No)	4.76 (1.13-20.04)	0.034	-	
Treatment period		0.46		
≤ 11 <sup>th</sup> week of 2020	1.00 (ref)		-	
12 <sup>th</sup> week of 2020	1.03 (0.41-2.59)		-	
13 <sup>th</sup> - 14 <sup>th</sup> week of 2020	0.62 (0.22-1.70)		-	
Time from symptoms (>7 vs ≤ 7 days)	0.93 (0.44-1.98)	0.86	-	
Il-6 (1-unit on log-scale)	1.93 (1.38-2.70)	<0.001	1.87 (1.29-2.71)	0.001
Ferritin (1-unit on log-scale)	1.20 (0.78-1.83)	0.41	-	

CRP (1-unit on log-scale)	1.62 (1.02-2.57)	0.04	-	
D-dimer (1-unit on log scale)	1.62 (1.19 - 2.21)	0.002	-	
PaO <sub>2</sub> /FiO <sub>2</sub> <100 vs ≥100 mmHg	2.70 (1.09-6.66)	0.032	1.88 (0.72-4.70)	0.14
NIV	1.99 (0.90-4.40)	0.090	-	

502 CRP, C reactive protein; HR: hazard-ratio; IL-6, interleukin 6; NIV, non invasive ventilation;

503 PaO<sub>2</sub>/FiO<sub>2</sub>, ratio of partial pressure of arterial oxygen to fractional concentration of oxygen

504 inspired air.

505 **Figure legends**

506 Figure 1

507 The flowchart of the included patients.

508

509 Figure 2

510 Adjusted failure-free (intubation or death) survival in patients who received tocilizumab

511 and/or methylprednisolone and standard of care (SOC) vs. SOC.

512

513 Figure 3

514 Adjusted failure-free survival in patients receiving anti-inflammatory treatment: tocilizumab

515 only, methylprednisolone only, and combined treatment.


516

517 Figure 4

518 Adjusted overall survival in patients who received tocilizumab and/or methylprednisolone and


519 standard of care (SOC) vs. SOC.

520



\* These two groups were included in the main landmark analysis






**Patients at risk**

SOC	66	66	66	64	61	58	55	51	49	47	47	45	44	44	42	41	40	32	25	23	20
Tocilizumab/methyl+ SOC	130	130	130	125	120	118	112	109	105	104	103	103	101	99	96	94	91	88	88	88	87





Patients at risk

SOC	66	66	66	64	62	59	56	52	49	48	48	46	46	46	44	43	42	34	27	25	22
Tocilizumab/methyl + SOC	130	130	130	128	127	126	121	119	115	114	112	112	111	109	106	104	99	95	95	95	94